

# 1 Title

2

3 Protocol for a Magnetic Resonance Imaging (MRI) Study of Participants in the Fever  
4 Randomized Controlled Trial: Does fever control prevent brain injury in malaria?

5

6

## 7 Names of protocol contributors

8 Moses B. Chilombe<sup>1</sup>, Karl B. Seydel<sup>1,2</sup>, Colleen Hammond<sup>3</sup> Suzanna Mwanza<sup>4</sup>, Archana A. Patel<sup>5</sup>,  
9 Frank Lungu<sup>6</sup>, Somwe wa Somwe<sup>6</sup>, Sam Kampondeni<sup>7,8</sup>, Michael J. Potchen<sup>8,9</sup>, Michael P.  
10 McDermott<sup>10,11</sup>, Gretchen L. Birbeck<sup>6,11</sup>

11

12

## 13 Affiliations

14 1 Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi

15 2 Department of Osteopathic Medical Specialties, Michigan State University, East Lansing,  
16 Michigan, USA

17 3 Department of Radiology, Michigan State University, East Lansing, Michigan, USA

18 4 Department of Pediatrics and Child Health, Chipata Central Hospital, Chipata, Zambia

19 5 Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA

20 6 University Teaching Hospitals Children's Hospital, Neurology Research Office, Lusaka,  
21 Zambia

22 7 Mpingwe Clinic, Limbe, Malawi

23 8 Department of Imaging Sciences, University of Rochester, Rochester, New York, USA

24 9 Zambia College of Medicine and Surgery, Lusaka, Zambia

25 10 Department of Biostatistics and Computational Biology, University of Rochester, Rochester,

26 New York, USA

27 11 Department of Neurology, University of Rochester, Rochester, New York, USA

28

29 **\*Corresponding Author**

30 Gretchen L. Birbeck

31 Email: [gretchen\\_birbeck@urmc.rochester.edu](mailto:gretchen_birbeck@urmc.rochester.edu)

32

33

34 **Protocol version**

35 Version 7.0 24June21

36

## 38 **Abstract**

39

## 40 **Background**

41 Despite eradication efforts, ~135,000 African children sustained brain injuries as a result of  
42 central nervous system (CNS) malaria in 2021. Newer antimalarial medications rapidly clear  
43 peripheral parasitemia and improve survival, but mortality remains high with no associated  
44 decline in post-malaria neurologic injury. A randomized controlled trial of aggressive antipyretic  
45 therapy with acetaminophen and ibuprofen (Fever RCT) for malarial fevers being conducted in  
46 Malawi and Zambia began enrollment in 2019. We propose to use neuroimaging in the context  
47 of the RCT to further evaluate neuroprotective effects of aggressive antipyretic therapy.

48

## 49 **Methods**

50 This observational magnetic resonance imaging (MRI) ancillary study will obtain neuroimaging  
51 and neurodevelopmental and behavioral outcomes in children previously enrolled in the Fever  
52 RCT at 1- and 12-months post discharge. Analysis will compare the odds of any brain injury  
53 between the aggressive antipyretic therapy and usual care groups based upon MRI structural  
54 abnormalities. For children unable to undergo imaging without deep sedation,  
55 neurodevelopmental and behavioral outcomes will be used to identify brain injury.

56

## 57 **Discussion**

58 Neuroimaging is a well-established, valid proxy for neurological outcomes after brain injury in  
59 pediatric CNS malaria. This MRI ancillary study will add value to the Fever RCT by determining if  
60 treatment with aggressive antipyretic therapy is neuroprotective in CNS malaria. It may also help

61 elucidate the underlying mechanism(s) of neuroprotection and expand upon FEVER RCT safety  
62 assessments.

63

## 64 **Keywords**

65 Seizures; neuro-disabilities; aggressive antipyretic therapy; neuroimaging; neurologic sequelae;  
66 neuroprotection; CNS malaria; neurodevelopment; neurobehavior

67

## 68 Introduction

## 69 Background

70 Central nervous system (CNS) malaria, meaning *P. falciparum* parasitemia with neurologic  
71 symptoms including impaired consciousness and/or seizures,<sup>1-4</sup> continues to be a major cause  
72 of neuro-disabilities in African children. Brain injury with subsequent neurologic sequelae occurs  
73 in one-third of children who survive CNS malaria. Newer antimalarial medications rapidly clear  
74 peripheral parasitemia and improve survival, but mortality remains high with no documented  
75 decline in post-malaria neurologic injury.<sup>5</sup> Common sequelae include epilepsy, gross motor  
76 deficits, blindness, cognitive impairment, and behavioral disorders.<sup>1-4, 6-8</sup>

77  
78 In the Blantyre Malaria Project Epilepsy Study (BMPES), a higher maximum temperature  
79 (Tmax) during the acute infection was associated with a greater risk of post-malaria neurologic  
80 sequelae. Children who developed epilepsy had a mean Tmax of 39.4°C vs. 38.5°C in those  
81 who did not develop epilepsy (absolute difference of 0.9°C; p=0.01). In addition, those with  
82 subsequent behavioral disorders had a higher Tmax than those who did not (39.2°C vs. 38.7°C;  
83 absolute difference 0.5°C; p=0.04).<sup>1</sup> These data are consistent with the substantial body of  
84 evidence that, within the peri-insult period, fevers contribute to secondary neurologic injury  
85 across a wide range of conditions including stroke, meningitis, anoxia, hypoxia, and trauma.<sup>9-13</sup>  
86 In the United States (US), induced hypothermia is now standard-of-care for post-anoxic<sup>14</sup> and  
87 neonatal hypoxic-ischemic encephalopathy<sup>15-18</sup> and fever prevention is an important aspect of  
88 neurocritical care.<sup>19-22</sup> In contrast to this aggressive and proactive approach to fever control, the  
89 World Health Organization (WHO) malaria care guidelines recommend only modest measures  
90 for fever control and these are to be used only in response to a significant febrile event.

91 Specifically, WHO malaria guidelines recommend treating a core temperature of  $\geq 38.5^{\circ}\text{C}$  with  
92 acetaminophen 15 mg/kg (no loading dose) and explicitly recommend against the use of other  
93 non-steroidal medications.<sup>23</sup> Malaria-induced fevers can be extremely high and there is no  
94 evidence to date that a single antipyretic reduces malaria fevers. A controlled trial of  
95 acetaminophen vs. placebo for uncomplicated malaria found no differences in mean  
96 temperature, but 4% of children receiving placebo required admission for febrile seizures.<sup>24</sup> In  
97 BMPEs, WHO malaria care guidelines were followed and 15% of children experienced at least  
98 one temperature of  $\geq 40.0^{\circ}\text{C}$ . The age-related susceptibility to pediatric malaria substantially  
99 overlaps with the age-related phenomena of febrile seizures. Malarial seizures are often  
100 complex, multifocal, and prolonged with status epilepticus being common.<sup>1, 7, 25, 26</sup> No malaria  
101 studies to date have evaluated the impact of interventions using two antipyretics.

102

103 In 2019, a randomized controlled trial of aggressive antipyretic therapy for CNS malaria (Fever  
104 RCT) launched in Malawi and Zambia.<sup>27</sup> This RCT compares prophylactic, scheduled  
105 acetaminophen, including an initial loading dose of 30 mg/kg, plus ibuprofen for 72 hours after  
106 presentation with CNS malaria to usual care based upon WHO guidelines over that same  
107 period. The primary outcome of the RCT is Tmax. This observational MRI ancillary study will  
108 determine whether the aggressive antipyretic therapy used in the Fever RCT resulted in fewer  
109 brain injuries based upon neuroimaging or neurodevelopment and behavioral outcomes where  
110 safe imaging is not possible.

111

## 112 **Rationale**

113 While a higher Tmax is associated with adverse neurologic outcomes in CNS malaria, causality  
114 is not established. CNS malaria is a highly inflammatory process<sup>28, 29</sup> and inflammation-

115 mediated injury is a likely pathway for malaria-associated brain injury in this population,  
116 particularly for epilepsy development. The aggressive antipyretic (AA) regimen used in the  
117 Fever RCT may offer anti-inflammatory benefits in addition to fever-reduction. Neuroimaging of  
118 the Fever RCT participants will facilitate identification of possible neuroprotective benefits from  
119 AA treatment including anti-inflammatory benefits that might not be evident based upon acute  
120 temperature measures. Previous research among cerebral malaria survivors in Blantyre has  
121 shown that 53% suffer from cognitive and/or behavioral impairments at one year and these  
122 impairments were associated with structural brain lesions on MRI including severe atrophy and  
123 multifocal abnormalities.<sup>30</sup>

124

125 This study will also expand the safety assessments of the AA intervention. Ibuprofen may cause  
126 bleeding due to its antiplatelet effects and is also nephrotoxic. Though frank CNS bleeds are not  
127 associated with pediatric cerebral malaria,<sup>31</sup> end vessel micro-hemorrhages are seen post  
128 mortem<sup>32, 33</sup> and have been identified on brain MRIs.<sup>34, 35</sup> MRI gradient recalled echo (GRE)  
129 sequences available on standard MR equipment are sensitive to ferromagnetic substances and  
130 will detect micro-hemorrhages. In Zambia where standard imaging is available, we will compare  
131 the presence and characteristics of any CNS bleeding in the AA vs usual care (UC) groups.  
132 Newly published data emerged after the Fever RCT commenced that shows a link between  
133 cerebral malaria, acute kidney injury and the development chronic kidney disease (CKD),<sup>36</sup> so  
134 the development of CKD after CNS malaria will also be compared using creatinine and the urine  
135 albumin:creatinine ratio (ACR) assessed at least 6-months post-recovery.

136

## 137 **Main Objectives**

138 This prospective observational study will seek consent from parents of children previously  
139 enrolled in the Fever RCT (Aggressive Antipyretics in CNS Malaria: A Randomized Controlled  
140 Trial Assessing Antipyretic Efficacy and Parasite Clearance; National Institutes of Health Grant  
141 R01NS102176; ClinicalTrials.gov NCT03399318) to obtain neuroimaging and  
142 neurodevelopmental & behavioral outcomes data on their child. The imaging and evaluations for  
143 this observational study will occur after the child has recovered from the acute malaria infection  
144 and has otherwise completed the Fever RCT study. For some, consent will be sought months  
145 after the RCT-related activities for the child are completed. As such, this is an independent  
146 observational study.

147

## 148 **Specific Aims**

149 Aim 1:

150 To compare the prevalence of brain injury in the AA vs UC groups of the Fever RCT. Children  
151 will undergo brain MRIs and neurodevelopmental & behavioral evaluations at 1 and 12 months  
152 after their acute malaria illness or as soon as possible among those children enrolled in the  
153 Fever RCT prior to the initiation of this MRI ancillary study. Two radiologists, blinded to  
154 treatment allocation, will independently review images and capture data using NeuroInterp.<sup>37</sup>  
155 For children who are unable to undergo imaging without deep sedation, neurodevelopmental &  
156 behavioral evaluations will be used to identify those with brain injury.

157 We hypothesize that children who receive AA therapy during CNS malaria will have lower odds  
158 of brain injury than those receiving UC.

159

160 Aim 2:



- 161 To compare the prevalence of specific structural injuries among children who received AA  
162 therapy vs. UC therapy in the Fever RCT. Specifically, we will compare
- 163 a. Overall atrophy by brain volume scoring<sup>38</sup> (atrophy being a brain volume score of 1-2 vs  
164  $\geq 3$ )
  - 165 b. Gliosis by Fazekas score<sup>39</sup> (0, 1, 2 or 3)
  - 166 c. The presence of regional gliosis or atrophy in the following regions
    - 167 1. Cortical (present/absent)
    - 168 2. Deep grey (present/absent)
    - 169 3. Corpus callosum (present/absent)
    - 170 4. Posterior fossa (present/absent)

171

172 *A priori* pathophysiologic attributions are as follows:

173 -If focal cortical abnormalities are lower for the AA treatment group, we will conclude that the  
174 mechanism(s) included seizure control/prevention

175 -If abnormalities are less common in the deep grey regions for the AA treatment group, we will  
176 attribute this to benefits of reduced sequestration in the deep vascular beds

177 -If there is less diffuse atrophy or overall gliosis for the AA treatment group, we will attribute this  
178 to reductions in increased intracranial pressure

179

180 Aim 3: Safety assessments

- 181 a. In Zambia where standard imaging with GRE sequences is available, we will compare  
182 the prevalence of blood products in the AA vs UC groups. If present, blood products will  
183 be further characterized by age of blood relative to participation in the Fever RCT and  
184 blood volume based upon number and size of foci.
- 185 b. The prevalence of CKD based upon blood creatinine and urine ACRs will be compared

186 in the AA vs UC groups

187

## 188 **Methods**

189 All patient-contact will occur in Zambia and Malawi. All data transmitted or conveyed

190 beyond the country of enrollment will be de-identified.

191

## 192 **Study sites**

193 • University Teaching Hospitals-Children’s Hospital, Lusaka,

194 • Chipata Central Hospital, Chipata, Zambia

195 • Queen Elizabeth Central Hospital, Blantyre, Malawi

196

197 Study sites without patient contact or access to data with private health information include:

198 • University of Rochester, Rochester, NY, USA

199 • Michigan State University, East Lansing, MI, USA

200

## 201 **Study design**

202 Consented participants from the Fever RCT will undergo (1) a non-contrast brain MRI, (2)

203 neurodevelopmental & behavioral assessment, and (3) kidney function assessments with

204 blood creatinine and urine ACR studies at 1 and 12 months post recovery, or as soon as

205 possible if their Fever RCT admission occurred prior to the launch of this observational study.

206 Based upon planned enrollment for the RCT (284), and considering anticipated mortality and  
207 loss to follow-up, expected enrollment is 184 total.

208

## 209 **Subject population**

210 All children enrolled in the Fever RCT who survive to discharge are eligible for enrollment.

211 Inclusion and exclusion criteria for the Fever RCT are outlined below.

212

## 213 **Eligibility criteria**

### 214 Inclusion Criteria for RCT

- 215 • Age 2-11 years (24 to 132 months)
- 216 • Evidence of *P. falciparum* malaria infection by peripheral blood smear or rapid diagnostic  
217 test
- 218 • CNS symptoms associated with malaria. This includes the most severe manifestation,  
219 that being cerebral malaria (CM) with impaired consciousness via Blantyre Coma Score  
220 (BCS)  $\leq 2$  in children under 5 years or a Glasgow Coma score (GCS)  $\leq 10$  in children  $\geq 5$   
221 years; or less severe disease with complicated seizure(s), meaning prolonged ( $>15$   
222 minutes), focal or multiple; or other evidence of impaired consciousness (confusion,  
223 delirium) without frank coma (BCS $>2$ , GCS=11-14)

224

### 225 Exclusion Criteria for RCT

- 226 • Circulatory failure (cold extremities, capillary refill  $> 3$  seconds, sunken eyes, decreased  
227 skin turgor)
- 228 • Vomiting in the past 2 hours

- 229 • Serum Cr > 1.2 mg/dL
- 230 • A history of liver disease
- 231 • Jaundice or a total bilirubin of >3.0mg/dL
- 232 • A history of gastric ulcers or gastrointestinal bleeding
- 233 • A history of thrombocytopenia or other primary hematologic disorder
- 234 • Petechiae or other clinical indications of bleeding abnormalities
- 235 • A known allergy to ibuprofen, acetaminophen, aspirin, or any non-steroidal medication
- 236 • Any contraindication for nasogastric tube placement and/or delivery of enteral
- 237 medications

238

## 239 **Recruitment Methods**

240 For children enrolled in the Fever RCT before this MRI ancillary study was commenced, consent  
241 for future contact regarding possible research participation in subsequent relevant studies was  
242 sought from the parents/guardians. This process was approved by the appropriate ethical and  
243 institutional review boards. A list of those who consented by study identifiers (IDs) will be cross-  
244 referenced to the contact details including address and cell phone numbers maintained in the  
245 study pharmacies. These parents/guardians will be contacted to seek consent for enrollment in  
246 this observational study. If the parent/guardian is willing to consider enrollment, they will be  
247 invited to come to the hospital for a full discussion and the consent process detailed below.

248 Children enrolled in the Fever RCT after this MRI ancillary study is launched will be identified as  
249 potential participants when they have been stabilized and regained consciousness. Study  
250 nurses working on the ward where the children are admitted will then approach the  
251 parent/guardian for consent prior to discharge.

252

## 253 **Consent Process**

254 For children whose parents consented to be contacted regarding future studies, phone calls will  
255 be placed and a brief overview of the study will be provided.

256

257 Consent and assent forms will be developed in English and the applicable local language.

258 Forward- and back- translation will be undertaken by expert local staff with extensive experience

259 in this regard. Staff obtaining consent are fluent in the local languages and expert in conducting

260 the informed consent discussion. All have Human Subjects Protection and Good Clinical

261 Practice certifications. The consent process will be conducted in the preferred language of the

262 parent/guardian. All parents/guardians who consent will be provided with signed copies of the

263 consent forms. For those parents/guardians who are unable to sign due to literacy limitations, a

264 thumb print will be obtained and someone who is not associated with the study but is literate in

265 the parent's/guardian's preferred language will be present during the consent process and will

266 sign as a witness. At the time of the return visit for evaluations, for children 7 years or older, if in

267 the parent's/guardian's assessment the child has the capacity to comprehend the nature of the

268 request, assent will also be sought.

269

## 270 **Study Procedures**

### 271 *Imaging*

272 In Zambia, a 0.35T GE MRI will be used to obtain T1, T2 FRFSE, FLAIR, diffusion-weighted

273 imaging, GRE, GRE T2\*, proton density, STIR and 2-D and volumetric imaging. In Malawi, a

274 Hyperfine MRI adjacent to the research ward will be used and provides please insert. MRI

275 images will be reviewed by the technician at the time of the scanning and any findings of

276 concern that might warrant gadolinium administration will be reviewed by one of the study  
277 radiologists in real time to allow for gadolinium administration when the child is initially imaged.  
278 However, if on review of an MRI about which the technical staff had no concerns the radiologist  
279 feels gadolinium is warranted for clinical care, the patient's family will be notified and all the  
280 same financial and logistical support will be provided for this repeat image. Two radiologists,  
281 blinded to treatment allocation and neurologic status, will independently review images and  
282 capture data using NeuroInterp. Disagreements will be reconciled first by consensus review and  
283 if reviewers still disagree, a third reader will make the final determination.

284

#### 285 *Neurodevelopmental & Behavioral*

286 At the 1- and 12-month evaluations, age-appropriate assessments will be undertaken by  
287 dedicated local staff fully trained to deliver these measures. Data entry will be on tablets at the  
288 time of assessment. See Table 1 for details regarding instruments and criteria for a child to be  
289 categorized as brain injured.

290

291 Table 1: Neurodevelopmental & Behavioral Assessments and Ages for Testing

<u>Instrument</u>	<u>Age</u>	<u>Criteria for Brain Injury</u>
Malawi Developmental Assessment Tool (MDAT) <sup>40</sup>	3-5 years 11 months	≥ 2 standard deviations below the mean compared to age-specific Malawian norms
Neurological examination for subtle signs (NESS) <sup>41</sup>	7 years and above	Positive findings will be referred for clinical review and confirmation.

Behavioral Rating Inventory of Executive Function (BRIEF) <sup>42</sup>	Preschool School	2 years to 5 years 11 months 6 years and up	≥ 2 standard deviations below the mean compared to previously established Western norms
Kaufman Assessment Battery for Children (KABC) <sup>43</sup>	Preschool School	6 years to 6 years 11 months 7 years and up	≥ 2 standard deviations below the mean compared to age-specific Malawian norms
World Health Organization Epilepsy Screening Questionnaire <sup>44</sup>		All ages	Positive screen for epilepsy

292

293

294 *Kidney Function*

295 Cr will be determined based upon analysis of whole blood captured via finger prick using a  
 296 STAT Sensor Creatinine Meter. Urine samples will be obtained for ACR measurements as well.  
 297 In Zambia, these will be obtained through a commercial lab. In Malawi, these will be assessed  
 298 with simultaneous measurement of urine albumin and creatinine on a Beckman Coulter AU480  
 299 machine with subsequent calculation of the ratio of the two analytes.

300

301 If any clinically relevant findings are identified, these will be discussed with the parent/guardian  
 302 and the appropriate referral for care will be made.

303

## 304 **Dissemination**

305 Findings from this work will initially be presented at appropriate local venues before broader  
306 dissemination. For example, University Teaching Hospital's Neurology Research-in-Progress  
307 weekly meeting in Lusaka, Zambia; Zambia's Annual National Health Research Conference in  
308 Lusaka, Zambia; the Wellcome Trust's Cutting-Edge weekly meeting, in Blantyre, Malawi and/or  
309 Kamuzu University of Health Science's Research Dissemination Day in Blantyre, Malawi. With  
310 approvals from Zambia's National Health Research Authority, findings will then be submitted to  
311 peer reviewed journal(s) for publication and wider dissemination. Copies of published papers  
312 will be submitted to the associated ethical review boards and the Zambian National Health  
313 Research Authority.

314

## 315 **Risks to Subjects**

316 Risks include loss of privacy, pain from finger prick, annoyance at the study assessments and  
317 adverse effects from sedation. MRI-specific risks are largely associated with implanted devices,  
318 which are not in use in the study populations of interest.

319

320 The study assessments including the neuroimaging are expected to take less than 2 hours.  
321 Regarding sedation risks--in our experience, Zambian and Malawian children as young as 6  
322 years are able to tolerate clinical MRIs without sedation with a parent in the scanning room to  
323 comfort and encourage them. In Malawi, an existing sedation protocol utilizing chloral hydrate  
324 that has been in place for several years will be used. No serious adverse events have occurred  
325 in relation to chloral hydrate use in Malawi to date. An estimated 6% of Malawian children given  
326 chloral hydrate develop a paradoxical hypervigilance sometimes with irritability and agitation



327 lasting 4-6 hours. Nausea, vomiting and an allergic reaction are listed side effects of chloral  
328 hydrate though these have not been seen during clinical use in children in Malawi over the last  
329 decade. Children with a history of an allergy to or adverse reactions to chloral hydrate and those  
330 with a history of a paradoxical response to other sedatives will not undergo sedation. Side  
331 effects for chloral hydrate are dose related. Although standard protocol for clinical use of chloral  
332 hydrate indicates repeated dosing if needed, no repeat dosing will be undertaken in this study.  
333 Children who cannot cooperate sufficiently for MRI acquisition and for whom sedation is  
334 deemed inappropriate or unsuccessful will not be imaged and their performance on the  
335 neurodevelopmental and behavioral assessments will be used to identify brain injury.

336

337 In Zambia where chloral hydrate is not available, an alternative sedation strategy will be used--  
338 melatonin plus diphenhydramine. Melatonin is the standard sedative used for pediatric  
339 electroencephalography in Zambia. Diphenhydramine in doses approved for over-the-counter  
340 treatment of cold symptoms in children in Zambia will be added to the melatonin. Should a child  
341 experience any adverse effects from sedation, a study clinician will evaluate them immediately.  
342 Most anticipated side effects are self-limited and will resolve without intervention. If needed, the  
343 clinician will provide analgesics for headache, anti-emetics for nausea, and oral rehydration  
344 solution for vomiting.

345

## 346 **Potential Benefits to Subjects**

347 Children identified as having neurologic sequelae or kidney injury based upon the evaluations  
348 will be referred for appropriate services that are available free of charge at both study sites.

349

## 350 **Cost of Participation**

351 Participants and their families will not be required to cover any of the costs associated with  
352 participation. All study activities and procedures, as well as round trip transportation for the  
353 children and their parents/guardians for these follow-up assessments, will be provided free-of-  
354 charge.

355

356 Payment for participation

- 357 • In Malawi, for each study visit families will be reimbursed for the roundtrip travel costs  
358 for the child and guardian. They will also receive remuneration consistent with  
359 published guidelines, which is MWK4500.<sup>45</sup>
- 360 • In Lusaka, for each study visit families will be reimbursed for the roundtrip travel costs  
361 for the child and guardian. They will also receive a total of ZMW260 for their time lost  
362 from work, food during the testing day and their child's completion of the assessments.
- 363 • In Chipata, for each study visit we will provide round trip transportation and overnight  
364 accommodation for the child and a parent/guardian to travel to Lusaka. They will also  
365 receive ZMW1060 for their time lost from work, food while traveling and the child's  
366 completion of the assessments.

367

## 368 **Subject withdrawals**

369 Parents/guardians may withdraw their children from the study at any time without impacting the  
370 child's clinical care or any other adverse consequences.

371

## 372 **Privacy and Confidentiality of Subjects and Research Data**

373 To limit risk of loss of privacy, only the study ID number will identify all laboratory specimens,  
374 evaluation forms, reports, and other records that leave the sites. All paper records will be kept in

375 secure study offices in locked filing cabinets. All computer entry and networking programs will  
376 be done using study IDs only. Study data using only study IDs will be stored as follows: paper-  
377 based in the secure study offices at each site available only to study staff; neurodevelopmental  
378 & behavioral outcomes and NeuroInterp data on the University of Rochester's Research  
379 Electronic Data Capture (REDCap) and Malawi Malaria Alert Centre (MAC) server, and  
380 neuroimaging files in DropBox with secured folders accessible only to study staff. Study staff will  
381 ensure that imaging data and scanned paper-based forms with graphical or pictorial data  
382 contain only the study ID and are saved in secured DropBox (i.e., non-public) folders. The study  
383 offices are secured rooms with lockable file cabinets. All computers are password-protected.  
384 DropBox folders containing de-identified data are non-public.

385  
386 Clinical information will not be released without permission of the participant's parent or  
387 guardian, except as necessary for monitoring by the appropriate institutional review boards  
388 (IRBs), the US National Institute of Neurological Disorders and Stroke, the US Office for Human  
389 Research Protections, the sponsor, or the sponsor's designee. If a family needs to be re-  
390 contacted for any reason (e.g., an imaging finding that is determined to warrant clinical follow-  
391 up), the study ID in this observational study will be cross-referenced against the contact details  
392 for each child's family that are maintained as required in the study pharmacy for the RCT.

393

### 394 **Possible constraints**

395 This MRI ancillary study will commence after the Fever RCT is underway and as such we  
396 anticipate some loss to follow-up even among those who consent for future contact prior to  
397 discharge from the Fever RCT study.

398

## 399 **Data/Sample storage**

400 De-identified imaging and neurodevelopmental & behavioral outcomes will be stored for future  
401 use in secured DropBox folders and on the University of Rochester and Blantyre-based Malaria  
402 Alert Centre servers.

403

## 404 **Data and Safety Monitoring Plan**

405 This is an observational study. Potential adverse events include breach in confidentiality and  
406 any injuries or inconveniences related to participation in the clinical assessments and/or imaging  
407 acquisition. Any adverse events identified will be reported to the appropriate institutional review  
408 boards. Although not anticipated, should any Serious Adverse Events occur during the conduct  
409 of this observational study, the Local Study Monitors serving the RCT will be asked to review  
410 with their assessments provided to the overseeing IRBs.

411

## 412 **Data Analysis Plan**

413 The analysis of the presence of a brain injury (yes/no) will involve fitting a logistic regression  
414 model with RCT treatment allocation group as the factor of interest, country as a stratification  
415 factor, and a stratified propensity score<sup>46</sup> to account for the fact that the treatment groups will no  
416 longer be the original randomized groups due to participants refusing consent and loss-to-  
417 follow-up. The propensity score will be estimated using a logistic regression model with  
418 treatment group as the outcome variable and baseline covariate information that is thought to be  
419 relevant to predicting adverse neurological outcome. These covariates include disease severity  
420 (presence/absence of cerebral malaria), seizures prior to admission, admission temperature,  
421 admission creatinine, sex, and age. The estimated treatment group odds ratio, along with its

422 associated 95% confidence interval and p-value, will be derived from this model. Similar  
423 analyses will be conducted for the other outcomes of interest including the presence of the  
424 specific imaging outcomes outlined in Aim 2, the presence of blood products; and the  
425 prevalence of chronic kidney disease based upon an ACR of >1.2. For the ordinal gliosis  
426 outcomes in Aim 2, a proportional odds logistic regression model will be employed; if the  
427 proportional odds assumption appears to be seriously violated, a partial proportional odds  
428 logistic regression model or a multinomial logistic regression model will be used instead.

429

430 The sample size considerations are based on the logistic regression analyses to be performed  
431 in Aim 1. Preliminary data indicate that 34% of pediatric CM survivors in Malawi have abnormal  
432 brain MRIs at 1 month or a KABC falling at least 2 standard deviations below the population  
433 norms for those over 7 years.<sup>43</sup> A sample size of 184 subjects (92 per group) will provide > 85%  
434 power to detect a reduction in the percentage of subjects with structural injury from 35% in the  
435 UC group to 15% in the AA therapy group, using a two-tailed test and a 5% significance level.

436

## 437 **Ethics approval and consent to participate.**

438 Written informed consent will be obtained from all participant's parents or guardians.

439

440 Study approval will be obtained from the following oversight entities prior to the conduct of this  
441 work:

442

- 443 • The University of Zambia's Biomedical Research Ethics Committee FWA00000338
- 444 • The University of Malawi's College of Medicine Research Ethics Committee  
445 FWA00011868

- 446 • The University of Rochester’s Research Subjects Review Board (RSRB) FWA00009386
- 447 • An intra-institutional reliance agreement will be generated between the University of
- 448 Rochester’s RSRB and Michigan State University’s Biomedical Institutional Review
- 449 Board FWA00004556
- 450 • The National Health Research Authority in Zambia

451

452 No human subjects contact will occur at any of the US-based sites. All data exported to the US

453 will be de-identified prior to transfer. All RSRB determinations regarding this work will be shared

454 with the non-affiliated researchers in a timely fashion.

455

## 456 **Discussion**

457 When completed, this follow-up study of brain injury among children previously in the malaria

458 Fever RCT will determine whether AA treatment in the Fever RCT provided neuroprotection

459 benefits. This study may also help identify adverse events associated with AA treatment

460 including microhemorrhages and kidney injuring leading to CKD.

461

## 462 **Abbreviations**

463 BMPES – Blantyre Malaria Project Epilepsy Study

464 CNS – central nervous system

465 CM - Cerebral Malaria

466 MRI – Magnetic Resonance Imaging

467 MSU – Michigan State University

468 RCT – randomized controlled trial.

469 RSRB - The University of Rochester's Research Subjects Review Board  
470 Tmax – maximum temperature PI - Principal Investigator  
471 UNZA BREC - The University of Zambia's Biomedical Research Ethics Committee  
472 UR- University of Rochester  
473 UNZA BREC - The University of Zambia's Biomedical Research Ethics Committee  
474 UTH – University Teaching Hospital

475

## 476 **Authors' contributions**

477 **Conceptualization:** Karl B. Seydel, Gretchen L. Birbeck, Michael Potchen

478 **Funding acquisition:** Gretchen Birbeck.

479 **Imaging aspects:** Sam Kampondeni, Michael Potchen, Colleen Hammond

480 **Investigation:** Gretchen Birbeck, Suzanna Mwanza, Karl B. Seydel

481 **Methodology:** Gretchen Birbeck, Karl B. Seydel, Michael P. McDermott

482 **Project administration:** Moses Chilombe, Gretchen L. Birbeck, Suzanna Mwanza

483 **Resources:** Gretchen L. Birbeck.

484 **Supervision:** Moses B. Chilombe, Karl B. Seydel, Suzanna Mwanza

485 **Writing – original draft:** Karl B. Seydel, Gretchen L. Birbeck, Michael Potchen, Michael P.

486 McDermott

487 **Writing – review & editing:** Moses B. Chilombe, Gretchen Birbeck, Karl B. Seydel, Michael P.

488 McDermott

489

## 490 **Funding**

491 Funded by the US National Institutes of Health (NIH) Grant R01NS111057.and R35NS122265

492 The investigators will have full access to the final dataset without any contractual limitations.

493

## 494 **Declarations**

495 Moses Chilombe has no disclosures.

496 Karl B. Seydel has received funding from the US NIH

497 Colleen Hammond has no disclosures.

498 Suzanna Mwanza has no disclosures

499 Archana A. Patel has received funding from the US NIH

500 Frank Lungu has no disclosures.

501 Somwe wa Somwe has no disclosures.

502 Sam Kampondeni has no disclosures.

503 Michael J. Potchen has received funding from the US NIH and is a paid medical legal

504 consultant.

505 Michael McDermott has received funding from the US NIH.

506 Gretchen L. Birbeck has received funding from the US NIH and is a paid consultant for

507 BlueSpark Technologies.

## 508 **References**

509

510 1. Birbeck GL, Molyneux ME, Kaplan PW, et al. Blantyre Malaria Project Epilepsy Study  
511 (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors:  
512 a prospective cohort study. *Lancet Neurol* 2010;9:1173-1181.

513 2. Carter JA, Lees JA, Gona JK, et al. Severe falciparum malaria and acquired childhood  
514 language disorder. *Dev Med Child Neurol* 2006;48:51-57.

515 3. Carter JA, Mung'ala-Odera V, Neville BG, et al. Persistent neurocognitive impairments  
516 associated with severe falciparum malaria in Kenyan children. *J Neurol Neurosurg Psychiatry*  
517 2005;76:476-481.

518 4. Carter JA, Neville BG, White S, et al. Increased prevalence of epilepsy associated with  
519 severe falciparum malaria in children. *Epilepsia* 2004;45:978-981.



- 520 5. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment  
521 of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.  
522 *Lancet* 2010;376:1647-1657.
- 523 6. Carter JA, Ross AJ, Neville BG, et al. Developmental impairments following severe  
524 falciparum malaria in children. *Trop Med Int Health* 2005;10:3-10.
- 525 7. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological  
526 outcome of cerebral malaria. *Lancet Neurol* 2005;4:827-840.
- 527 8. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with  
528 long-term cognitive impairment. *Pediatrics* 2008;122:e92-99.
- 529 9. WHO. Severe and complicated malaria. World Health Organization, Division of Control of  
530 Tropical Diseases. *Trans R Soc Trop Med Hyg* 1990;84 Suppl 2:1-65.
- 531 10. Corbett D, Thornhill J. Temperature modulation (hypothermic and hyperthermic  
532 conditions) and its influence on histological and behavioral outcomes following cerebral ischemia.  
533 *Brain Pathol* 2000;10:145-152.
- 534 11. Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in  
535 patients with stroke and neurologic injury: a comprehensive meta-analysis. *Stroke* 2008;39:3029-  
536 3035.
- 537 12. Laptook AR, Corbett RJ. The effects of temperature on hypoxic-ischemic brain injury. *Clin*  
538 *Perinatol* 2002;29:623-649, vi.
- 539 13. Suz P, Vavilala MS, Souter M, Muangman S, Lam AM. Clinical features of fever associated  
540 with poor outcome in severe pediatric traumatic brain injury. *J Neurosurg Anesthesiol* 2006;18:5-  
541 10.
- 542 14. Arrich J, Holzer M, Herkner H, Mullner M. Cochrane corner: hypothermia for  
543 neuroprotection in adults after cardiopulmonary resuscitation. *Anesth Analg* 2010;110:1239.
- 544 15. Lin ZL, Yu HM, Lin J, Chen SQ, Liang ZQ, Zhang ZY. Mild hypothermia via selective head  
545 cooling as neuroprotective therapy in term neonates with perinatal asphyxia: an experience from  
546 a single neonatal intensive care unit. *J Perinatol* 2006;26:180-184.
- 547 16. Low E, Boylan GB, Mathieson SR, et al. Cooling and seizure burden in term neonates: an  
548 observational study. *Arch Dis Child Fetal Neonatal Ed* 2012;97:F267-272.
- 549 17. Schulzke SM, Rao S, Patole SK. A systematic review of cooling for neuroprotection in  
550 neonates with hypoxic ischemic encephalopathy - are we there yet? *BMC Pediatr* 2007;7:30.
- 551 18. Smit E, Liu X, Jary S, Cowan F, Thoresen M. Cooling neonates who do not fulfil the  
552 standard cooling criteria - short- and long-term outcomes. *Acta Paediatr* 2015;104:138-145.
- 553 19. Choi HA, Badjatia N, Mayer SA. Hypothermia for acute brain injury--mechanisms and  
554 practical aspects. *Nat Rev Neurol* 2012;8:214-222.

- 555 20. Corry JJ. Use of hypothermia in the intensive care unit. *World J Crit Care Med* 2012;1:106-  
556 122.
- 557 21. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics  
558 of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe  
559 substrates midazolam, caffeine, and digoxin. *Clin Pharmacol Ther* 2008;84:52-62.
- 560 22. Scaravilli V, Tincher G, Citerio G. Fever management in SAH. *Neurocrit Care*  
561 2011;15:287-294.
- 562 23. WHO. WHO Guidelines for Malaria. 2022;425. Available at: WHO-UCN-GMP-2022.01-  
563 Rev.2-eng.pdf. Accessed 13Aug23.
- 564 24. Kofoed PE, Ursing J, Rodrigues A, Rombo L. Paracetamol versus placebo in treatment of  
565 non-severe malaria in children in Guinea-Bissau: a randomized controlled trial. *Malar J*  
566 2011;10:148.
- 567 25. Chomba E, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL. The socioeconomic status  
568 of children with epilepsy in Zambia: implications for long-term health and well-being. *Epilepsy*  
569 *Behav* 2008;13:620-623.
- 570 26. Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status  
571 epilepticus in childhood cerebral malaria. *QJM* 1996;89:591-597.
- 572 27. Chilombe MB, McDermott MP, Seydel KB, Mathews M, Mwenechanya M, Birbeck GL.  
573 Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-  
574 controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER  
575 study). *PLoS One* 2022;17:e0268414.
- 576 28. Dammann O, Leviton A. Inflammation, brain damage and visual dysfunction in preterm  
577 infants. *Semin Fetal Neonatal Med* 2006;11:363-368.
- 578 29. Moxon CA, Chisala NV, Wassmer SC, et al. Persistent endothelial activation and  
579 inflammation after *Plasmodium falciparum* Infection in Malawian children. *J Infect Dis*  
580 2014;209:610-615.
- 581 30. Langfitt JT, McDermott MP, Brim R, et al. Neurodevelopmental Impairments 1 Year After  
582 Cerebral Malaria. *Pediatrics* 2019;143.
- 583 31. Potchen MJ, Kampondeni SD, Seydel KB, et al. Acute brain MRI findings in 120 Malawian  
584 children with cerebral malaria: new insights into an ancient disease. *AJNR Am J Neuroradiol*  
585 2012;33:1740-1746.
- 586 32. Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of  
587 parasitized erythrocytes in human *falciparum* malaria: a pathological study. *Am J Trop Med Hyg*  
588 1991;44:168-175.
- 589 33. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by  
590 postmortem parasite counts. *Nat Med* 2004;10:143-145.

- 591 34. Medhi N, Das SB, Das RR, et al. MRI findings of cerebral malaria. A report of two cases.  
592 *Neuroradiol J* 2009;22:407-412.
- 593 35. Rasalkar DD, Paunipagar BK, Sanghvi D, Sonawane BD, Loniker P. Magnetic resonance  
594 imaging in cerebral malaria: a report of four cases. *Br J Radiol* 2011;84:380-385.
- 595 36. Conroy AL, Opoka RO, Bangirana P, et al. Acute kidney injury is associated with impaired  
596 cognition and chronic kidney disease in a prospective cohort of children with severe malaria. *BMC*  
597 *Med* 2019;17:98.
- 598 37. Potchen MJ, Kampondeni SD, Ibrahim K, et al. NeuroInterp: a method for facilitating  
599 neuroimaging research on cerebral malaria. *Neurology* 2013;81:585-588.
- 600 38. Kampondeni SD, Birbeck GL, Seydel KB, et al. Noninvasive measures of brain edema  
601 predict outcome in pediatric cerebral malaria. *Surg Neurol Int* 2018;9:53.
- 602 39. Shu L, Zhong K, Chen N, et al. Predicting the severity of white matter lesions among  
603 patients with cerebrovascular risk factors based on retinal images and clinical laboratory data: a  
604 deep learning study. *Front Neurol* 2023;14:1168836.
- 605 40. Gladstone M, Lancaster GA, Umar E, et al. The Malawi Developmental Assessment Tool  
606 (MDAT): the creation, validation, and reliability of a tool to assess child development in rural  
607 African settings. *PLoS Med* 2010;7:e1000273.
- 608 41. Denckla MB. Revised Neurological Examination for Subtle Signs (1985).  
609 *Psychopharmacol Bull* 1985;21:773-800.
- 610 42. Waschl N, Khng KH, Bull R, Ng EL, Sun H, Chan WT. Screening for executive function  
611 difficulties: An evaluation of the Behavior Rating Inventory of Executive Function-2nd Edition  
612 Screener, Teacher Report (BRIEF2-TS). *Psychol Assess* 2023;35:366-377.
- 613 43. Brim R, Mboma S, Semrud-Clikeman M, et al. Cognitive Outcomes and Psychiatric  
614 Symptoms of Retinopathy-Positive Cerebral Malaria: Cohort Description and Baseline Results.  
615 *Am J Trop Med Hyg* 2017;97:225-231.
- 616 44. Placencia M, Sander JW, Shorvon SD, Ellison RH, Cascante SM. Validation of a  
617 screening questionnaire for the detection of epileptic seizures in epidemiological studies. *Brain*  
618 1992;115 ( Pt 3):783-794.
- 619 45. Gordon SB, Chinula L, Chilima B, et al. A Malawi guideline for research study participant  
620 remuneration. *Wellcome Open Res* 2018;3:141.
- 621 46. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a  
622 treatment to a non-randomized control group. *Stat Med* 1998;17:2265-2281.  
623